ACAD
31.35
-0.42
-1.32%
AEMD
3.855
-0.015
-0.3824%
APRI
1.51
+0.01
+0.37%
ARNA
1.38
-0.04
-2.82%
ATEC
3.56
+0.01
+0.28%
CNAT
4.93
-0.16
-3.14%
CRXM
0.18
0.00
+0.56%
CYTX
1.53
-0.05
-3.16%
DXCM
85.49
+0.36
+0.42%
GNMK
12.61
-0.14
-1.10%
HALO
10.89
-0.5
-4.39%
ILMN
160.47
-2.1
-1.29%
INNV
0.202
-0.008
-3.810%
INO
6.7
-0.28
-4.01%
ISCO
1
-0.03
-2.91%
ISIS
0
0.00
0.00%
LGND
101.46
-4.16
-3.94%
LPTN
2.93
0.00
0.00%
MBVX
3.25
-0.1
-2.99%
MEIP
1.54
+0.03
+1.99%
MNOV
6.12
-0.1
-1.61%
MRTX
5.45
+0.05
+0.93%
MSTX
0.138
+0.001
+0.656%
NBIX
40.17
-2.08
-4.92%
NUVA
69.65
-0.7
-1.00%
ONCS
1.34
-0.02
-1.47%
ONVO
3.55
-0.15
-4.05%
OREX
3.16
-0.17
-5.11%
OTIC
15.9
-0.85
-5.07%
QDEL
19.76
-0.17
-0.85%
RCPT
0
0.00
0.00%
RGLS
2.35
-0.1
-4.08%
RMD
64.18
-1.15
-1.76%
SCIE
0.001
0.00
-6.6667%
SPHS
2.9
+0.02
+0.69%
SRNE
5.35
-0.3
-5.31%
TROV
2.35
-0.05
-2.08%
VICL
2.33
+0.01
+0.37%
ZGNX
9.65
-0.7
-6.76%
ACAD
31.35
-0.42
-1.32%
AEMD
3.855
-0.015
-0.3824%
APRI
1.51
+0.01
+0.37%
ARNA
1.38
-0.04
-2.82%
ATEC
3.56
+0.01
+0.28%
CNAT
4.93
-0.16
-3.14%
CRXM
0.18
0.00
+0.56%
CYTX
1.53
-0.05
-3.16%
DXCM
85.49
+0.36
+0.42%
GNMK
12.61
-0.14
-1.10%
HALO
10.89
-0.5
-4.39%
ILMN
160.47
-2.1
-1.29%
INNV
0.202
-0.008
-3.810%
INO
6.7
-0.28
-4.01%
ISCO
1
-0.03
-2.91%
ISIS
0
0.00
0.00%
LGND
101.46
-4.16
-3.94%
LPTN
2.93
0.00
0.00%
MBVX
3.25
-0.1
-2.99%
MEIP
1.54
+0.03
+1.99%
MNOV
6.12
-0.1
-1.61%
MRTX
5.45
+0.05
+0.93%
MSTX
0.138
+0.001
+0.656%
NBIX
40.17
-2.08
-4.92%
NUVA
69.65
-0.7
-1.00%
ONCS
1.34
-0.02
-1.47%
ONVO
3.55
-0.15
-4.05%
OREX
3.16
-0.17
-5.11%
OTIC
15.9
-0.85
-5.07%
QDEL
19.76
-0.17
-0.85%
RCPT
0
0.00
0.00%
RGLS
2.35
-0.1
-4.08%
RMD
64.18
-1.15
-1.76%
SCIE
0.001
0.00
-6.6667%
SPHS
2.9
+0.02
+0.69%
SRNE
5.35
-0.3
-5.31%
TROV
2.35
-0.05
-2.08%
VICL
2.33
+0.01
+0.37%
ZGNX
9.65
-0.7
-6.76%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.

Be Sociable, Share!